The glioblastoma market, projected to be valued at USD 1.30 Billion in 2025, is anticipated to witness robust growth, reaching USD 3.12 Billion by 2032 at a CAGR of 13.3% during the forecast period. This growth is primarily driven by the rising incidence of glioblastoma, advancements in diagnostic imaging, and increasing adoption of targeted therapies and immunotherapies.

Significant investments in oncology research and the development of novel treatment modalities, including gene therapies and tumor-treating fields (TTFs), are further fueling the market expansion. Additionally, the growing emphasis on personalized medicine and improved patient access to clinical trials, especially in developed regions, is expected to strengthen the market outlook.

Market Takeaways

• By Epidemiology, the total incident cases of glioblastoma sub-segment is projected to dominate with a 39.5% market share in 2025, reflecting the high burden and recurrence rate of glioblastoma compared to other brain tumors, which necessitates aggressive treatment and long-term care.
• By Treatment, the surgery sub-segment is expected to hold the largest share of 35.2% in 2025, attributed to its critical role as the first-line intervention for tumor resection and improved survival outcomes when combined with radiation and chemotherapy.
• Regionally, North America is anticipated to lead the global glioblastoma market in 2025, driven by advanced healthcare infrastructure, high awareness and screening rates, robust research funding, and the early adoption of novel therapeutic modalities including immunotherapy and precision oncology.

Glioblastoma Market Report Coverage

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/glioblastoma-market

Market Dynamics

The glioblastoma market is experiencing strong growth, primarily fueled by the rising global incidence of brain tumors and the increasing need for effective, multi-modal treatment strategies. As one of the most aggressive and lethal forms of brain cancer, glioblastoma demands urgent and continuous innovation in diagnostics, surgical techniques, and therapeutic interventions. The standard of care includes surgery, radiotherapy, and chemotherapy, with a growing emphasis on combining these with targeted therapies and immunotherapies to enhance survival rates and quality of life.

Technological advancements in neuroimaging, molecular diagnostics, and intraoperative tools are improving early detection and precision in surgical tumor resection. Additionally, the emergence of tumor-treating fields (TTFs), gene therapies, and CAR-T cell therapy is expanding the treatment landscape and offering new hope for patients with recurrent glioblastoma.

In June 2025, researchers presented promising results at the American Society of Clinical Oncology (ASCO) meeting, revealing that a Gilead Sciences-backed CAR-T cell therapy shrank tumors in 62% of patients with recurrent glioblastoma—a significant milestone for a highly aggressive and treatment-resistant brain cancer. The therapy, which involves engineering a patient’s white blood cells to target and destroy cancer cells, marks a critical advancement in immunotherapy and was also published in Nature Medicine.

Pharmaceutical companies and academic institutions are actively investing in clinical trials focused on innovative treatment options and biomarker-based personalized therapies. Meanwhile, patient awareness campaigns and supportive regulatory pathways, particularly in North America and Europe, are accelerating access to novel therapies.

Regional market growth is further supported by increasing healthcare expenditure, improved infrastructure, and the establishment of specialized neuro-oncology centers in emerging markets. However, challenges such as high treatment costs, limited efficacy of existing therapies, and tumor heterogeneity continue to hinder optimal outcomes, underscoring the need for ongoing research and therapeutic breakthroughs.

Market Trends

• Rise of Next-Generation CAR-T and Dual-Target Immunotherapies

The glioblastoma treatment landscape is rapidly evolving with the development of advanced immunotherapies, including dual-target CAR-T cell therapies designed to overcome tumor heterogeneity and immune evasion. These treatments are engineered to target multiple glioblastoma-associated antigens, offering improved efficacy in managing recurrent and resistant cases.

In May 2025, the Journal of Translational Medicine report described the early-stage exploration of combining PSMA‑targeted and GD2‑targeted CAR‑T cells in refractory or relapsed glioma patients. This dual‑target strategy is intended to cover antigenic variability and improve efficacy.

• Personalized and Pre-Surgical Immunotherapy Approaches

There is a growing trend toward personalized immunotherapy, including pre-surgical immunomodulation and tumor-specific vaccine strategies, to improve treatment response and prolong survival in glioblastoma patients. These therapies aim to prime the immune system early and enhance post-operative outcomes.

In April 2024, Australian pathologist Mr. Richard Scolyer, diagnosed with grade 4 glioblastoma in June 2023, underwent an experimental regimen combining immunotherapy delivered before and after surgery, together with a personalized vaccine targeting his tumor. One year post‑diagnosis, no tumor recurrence was detected, demonstrating the promise of neoadjuvant immunomodulation in enhancing survival and clinical outcomes.

Market Opportunities

• Integration of Spatial Transcriptomics for Tumor Microenvironment Profiling in GBM Treatment Development

The complex tumor microenvironment (TME) of glioblastoma presents significant barriers to therapeutic efficacy. However, the rise of spatial transcriptomics technologies—such as 10x Genomics’ Visium platform and NanoString’s CosMx SMI—enables researchers to map gene expression at single-cell resolution within tissue context. In late 2024, several academic-industry partnerships began leveraging this approach to uncover immunosuppressive niches and resistance signatures in GBM.
This innovation facilitates precise target identification and therapy localization, allowing for tailored immunotherapies, anti-angiogenics, and cell-based therapies based on spatial gene expression patterns. As spatial omics tools transition from discovery to clinical application, they present a new frontier for high-resolution biomarker development, patient stratification, and response monitoring, especially in personalized glioblastoma care.

• Growing Interest in Onco-Neurorehabilitation and Supportive Digital Health Platforms

Due to the aggressive nature of glioblastoma and its impact on cognitive and physical functions, there is a rising need for integrative care approaches that combine oncology with neurorehabilitation. Startups like Neofect and MindMaze, and platforms like Kaiku Health, are developing AI-assisted tools to monitor neurological decline, support therapy adherence, and personalize rehabilitation.

In 2025, several European cancer centers began piloting digital platforms that combine GBM symptom tracking with behavioral interventions. This trend highlights a growing market for adjunctive, digital therapeutics and supportive technologies focused on improving the quality of life, functional recovery, and long-term care continuity in GBM survivors.

Analyst View

• The glioblastoma market is entering a high-growth phase, driven by scientific advancements in tumor biology, precision diagnostics, and immunotherapy platforms. Despite the inherent complexity and aggressiveness of glioblastoma, continuous innovation—particularly in CAR-T therapies, tumor-treating fields (TTFs), and spatial transcriptomics—is redefining clinical outcomes and expanding therapeutic possibilities.
• The shift toward personalized oncology is fostering development in tumor-specific vaccines, neoadjuvant immunomodulation, and biomarker-guided clinical trials. Successful cases of experimental immunotherapy regimens, such as those in Australia and the U.S., are reinforcing the viability of tailored treatment protocols that combine surgery with immunological priming.
• North America remains at the forefront of glioblastoma innovation, with supportive regulatory frameworks, significant R&D funding, and academic-industry collaborations accelerating clinical translation. Meanwhile, emerging economies in Asia and Latin America are witnessing infrastructure upgrades and rising patient enrollment in multinational trials, signaling future growth potential in untapped regions.
• In parallel, supportive care innovation—including digital neurorehabilitation, symptom monitoring apps, and patient-centric platforms—is creating adjacent market opportunities. These technologies aim to improve life quality and long-term management, particularly for survivors experiencing neurological deficits.
• Going forward, the glioblastoma market will be shaped by a dual trajectory: the integration of spatial and genomic data for high-resolution drug targeting, and the expansion of digitally enabled, multidisciplinary care ecosystems. Stakeholders that invest early in precision medicine, regulatory agility, and cross-functional patient support systems will gain a competitive advantage in this rapidly evolving landscape.

Recent Key Developments

• In March 2025, Bayer and Suzhou Puhe BioPharma Co., Ltd, a clinical-stage biotechnology company, today announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small-molecule PRMT5 inhibitor that selectively targets MTAP-deleted tumors. Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture, and commercialize the MTA-cooperative PRMT5 inhibitor. Bayer has enrolled the first participant in a Phase I first-in-human dose escalation study investigating MTA-cooperative PRMT5 inhibitor under the development name BAY 3713372 for the treatment of MTAP-deleted solid tumors.

Competitive Landscape

• Bayer
• Chimerix
• Aivita Biomedical
• Denovo Biopharma
• Northwest Therapeutics
• VBL Therapeutics
• Laminar Pharmaceuticals
• MedImmune
• DNAtrix
• Immunomic Therapeutics
• Imvax
• MimiVax
• CNS Pharmaceuticals
• Epitopoietic Research Corporation (ERC)
• Istari Oncology
• SonALAsense
• Kintara Therapeutics
• Bristol Myers Squibb
• Medicenna Therapeutics
• BioMimetix
• Eisai
• Merck Sharp & Dohme
• Kazia Therapeutics
• Oblato
• Genenta Science
• Enterome
• Inovio Pharmaceuticals
• Karyopharm Therapeutics
• Forma Therapeutics
• VBI Vaccines
• TME Pharma

Glioblastoma Market Segmentation

• By Glioblastoma Epidemiology
• Total Incident Cases of Glioblastoma
• Gender-specific Incidence
• Type-specific Incidence
• Age-Specific Incidence
• By Glioblastoma Treatment
• Surgery
• Chemotherapy
• Radiation Therapy
• Tumor Treatment Fields

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • France
  • Russia
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • Japan
  • China
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa